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Abstract
Background: Infection with Kaposi’s sarcoma-associated herpesvirus (KSHV/HHV8) often results in the development of fatal
tumors in immunocompromised patients. Studies of renal transplant recipients show that use of the immunosuppressant
drug rapamycin, an mTOR inhibitor, both prevents and can induce the regression of Kaposi’s sarcoma (KS), an opportunistic
tumor that arises within a subset of this infected population. In light of rapamycin’s marked anti-KS activity, we tested
whether the drug might directly inhibit the KSHV life cycle. We focused on the molecular switch that triggers this
predominantly latent virus to enter the lytic (productive) replication phase, since earlier work links this transition to viral
persistence and tumorigenesis.
Methods and Findings: In latently infected human B cell lines, we found that rapamycin inhibited entry of the virus into the
lytic replication cycle, marked by a loss of expression of the lytic switch protein, replication and transcription activator (RTA).
To test for viral-specific effects of rapamycin, we focused our studies on a B cell line with resistance to rapamycin-mediated
growth inhibition. Using this line, we found that the drug had minimal effect on cell cycle profiles, cellular proliferation, or
the expression of other cellular or latent viral proteins, indicating that the RTA suppression was not a result of global cellular
dysregulation. Finally, treatment with rapamycin blocked the production of progeny virions.
Conclusions: These results indicate that mTOR plays a role in the regulation of RTA expression and, therefore, KSHV
production, providing a potential molecular explanation for the marked clinical success of rapamycin in the treatment and
prevention of post-transplant Kaposi’s sarcoma. The striking inhibition of rapamycin on KSHV lytic replication, thus, helps
explain the apparent paradox of an immunosuppressant drug suppressing the pathogenesis of an opportunistic viral
infection.
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Introduction
The tumorigenic virus Kaposi’s sarcoma-associated herpesvirus
(KSHV, human herpesvirus 8 or HHV8) is the causative agent of
primary effusion lymphoma (PEL), multicentric Castleman’s
disease (MCD), and, most commonly, Kaposi’s sarcoma (KS)
[1,2]. KSHV, as with all herpesviruses, has both a latent phase in
which the virus expresses few proteins, as well as a lytic phase
during which virion production occurs. While the latent form of
viral infection is predominant both in KS lesions as well as within
PEL cells, maintenance of KSHV infection and subsequent
tumorigenesis in the setting of immunosuppression are dependent
on viral lytic replication and the subsequent infection of naı ¨ve
target cells by newly released virions [3,4]. Replication and
transcription activator (RTA), encoded by KSHV open reading
frame (ORF) 50, initiates the lytic protein cascade [5–7].
Moreover, expression of RTA is necessary and sufficient for
commencement of lytic replication [6]. In the laboratory setting,
the addition of specific chemical agents to latently infected cells
induces lytic reactivation. Valproic acid (VPA), for example,
activates KSHV likely through its role as a histone deacetylase
(HDAC) inhibitor [8]. KSHV also reactivates in the presence of
phorbol esters, such as 2-O-tetradecanoyl-phorbol-13-acetate
(TPA), that upregulate the Raf/MEK/ERK pathway [9] and
cobalt chloride, a hypoxia mimetic, that elevates levels of hypoxia
inducible factor-1 alpha (HIF-1a) [10,11]. While these three
induction pathways ultimately result in increased RTA expression,
it is unclear whether these signaling pathways are independent or,
instead, share regulatory control points upstream of RTA.
Recent reports have linked the immunosuppressant rapamycin
(sirolimus) to the regression of KS in renal transplant patients.
Since KSHV-induced diseases arise and progress primarily in
immunocompromised populations, the inhibition of PEL-like
tumors in an animal model using this treatment appears
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mammalian target of rapamycin (mTOR). mTOR is a highly
conserved kinase and a central component in signaling cascades
that modulate a wide range of metabolic processes. It is
particularly critical in promoting protein synthesis and cell cycle
progression (as reviewed in [20]). Pharmacological inhibition of
mTOR using rapamycin, therefore, can have a wide range of
effects, and significantly, may have a pronounced anti-neoplastic
effect on cells or tumors whose growth is dependent on high levels
of mTOR activity. Thus, it is noteworthy that other groups have
found that the mTOR pathway is highly active in KSHV-infected
cells and contributes to cell survival, growth and production of
angiogenic factors [15,21]. However, in light of the sensitive
balance between immune health and gammaherpesvirus induced
tumors, even the anti-proliferative effects of rapamycin seem
inadequate to fully explain the suppression and even regression of
KSHV-induced pathogenesis. Of particular interest is a clinical
study by Barozzi et al. wherein patients with post-transplant KS
treated with rapamycin show a drop in virus copy number that,
remarkably, precedes both the enhancement of KSHV-specific
immune responses and tumor regression [22]. This suggests that
either cells with lytic viral replication are particularly susceptible to
rapamycin treatment or, instead, there is a direct suppression of
virion production from KSHV
+ cells. We asked whether the drug
might play a more direct role in suppressing KSHV itself. We
investigated whether the lytic phase of the KSHV lifecycle is
especially sensitive to the inhibitory actions of rapamycin. We
hypothesized that rapamycin may block the essential transition of
KSHV from latency to lytic replication since low-level entrance
into this second phase of the viral lifecycle is essential for survival
of the virus in vivo and in vitro [3,4].
To test this hypothesis, we employed primary effusion lymphoma
cell lines, a tissue culture based system, for viral reactivation.
Consistent with its anti-neoplastic role, rapamycin can induce cell
cycle arrest in a number of KSHV
+ lymphoma cell lines [14].
Therefore, to test the role of mTOR signaling blockade specifically
on viral protein expression and virion production, we utilized a PEL
line that is refractory to rapamycin-dependent growth perturba-
tions. We found that mTOR played an essential role in RTA
expression, as rapamycin was sufficient to block reactivation in the
majority of cells irrespective of the route of lytic induction.
Methods
Cell culture
BCBL-1 cells [23] were grown in RPMI 1640 media (Gibco)
supplemented with 10% fetal bovine serum (FBS), 10 mM HEPES
(pH 7.5), 100 U/ml penicillin, 100 mg/ml streptomycin, 2 mM L-
glutamine, 0.05 mM b-mercaptoethanol, and 0.02% w/v sodium
bicarbonate. HeLa (American Type Culture Collection) cells were
grown in D-MEM (Gibco) media supplemented with 5% FBS and
2 mM L-glutamine.
Drug treatments
Virion production was induced with cobalt chloride (CoCl2)
(100 mM), O-tetradecanoylphorbol-13-acetate (TPA) (20 ng/mL),
or valproic acid (VPA) (300 or 600 mM). Cells were pre-treated
with indicated dose of Rapamycin (EMB Bioscience) or DMSO
vehicle control 2 hours prior to lytic induction.
Infection with KSHV
Virus was collected from induced BCBL-1 cells on the fifth day
after induction by centrifugation at 13,000xg for three hours as
previously described [24]. The viral pellet was resuspended in
one-two hundredth the original volume with PBS, and the
concentrated virus (stored at 4uC for up to 1 week without loss
in titer) was used to infect target HeLa cells in the presence of
8 mg/ml polybrene (Sigma Aldrich). For cell-associated infection,
BCBL-1 were treated with rapamycin, then on day 4 were plated
with HeLa cells at a ratio of 6:1 (BCBL-1: HeLa) overnight in the
presence of 8 mg/ml polybrene. HeLas were washed twice to
remove BCBL-1 cells, then trypsinized, fixed and permeabilized
with ice-cold MeOH/Acetone, rehydrated in ICSB and stained
for intracellular LANA. Rat anti-LANA antibody (Advanced
Biotechnologies) directly conjugated to AlexaFluor488 (Molecular
Probes) was used at 1:1000. Just prior to analysis cells were stained
with DRAQ5 at 50 mM to allow visualization of nuclei (BioStatus
Ltd, United Kingdom). Samples were run on the ImageStream100
(Amnis Corp., Seattle, WA) and analyzed using IDEAS software
3.0 (Amnis) to count number of LANA dots within nuclei of
infected HeLa cells.
DNA content analysis (cell cycle)
BCBL-1 cells were harvested two days following drug
treatments, washed once with cold 1x PBS, and resuspended in
cold 70% ethanol, followed by a two-hour (minimum) incubation.
Cells were then pelleted and resuspended in PBS, incubated for 1
minute, and re-pelleted before resuspending in PI staining solution
(0.1% v/v Triton X-100 in Tris buffered saline, 20 U/mL DNase-
free RNase A, and 5 mg/mL propidium iodide) and incubating
for 30 minutes at 20uC or 15 minutes at 37uC. DNA content was
measured on a FACS Calibur Flow Cytometer (BD) and analyzed
using the Modfit LT software (Verity Software House) [25].
Flow cytometry
BCBL-1 were harvested for analysis by flow cytometry at the
indicated times. Cells were resuspended in PBS and stained with
Live/Dead fixable Violet or Aqua exclusion dye (Molecular Probes,
Invitrogen) per manufacturer instructions to identify viable cells.
Cells were then fixed with 2% paraformaldehyde for 15 min.,
resuspended in cold Intracellular Staining Buffer (ICSB; 0.2%
Sodium Azide and 1% BSA in PBS), fixed with 2% paraformal-
dehyde for 15 minutes and permeabilized in 1X Perm/Wash (BD
Biosciences). Mouse monoclonal RTA antibody (a kind gift from K.
Ueda) was diluted 1:2000 in Perm/Wash. Anti-ORF59 and K8.1
monoclonal antibodies (Advanced Biotechnologies) were conjugat-
ed to Pacific Blue or Alexa Fluor647 fluorchromes (Invitrogen) and
titered before use at 1:500 and 1:5000 dilutions, respectively.
Polyclonal anti-mouse secondary antibody conjugated to APC or to
Cy3 (Jackson ImmunoResearch) was diluted 1:500 in Perm/Wash.
Flow cytometry was performed with a FACS Calibur Flow
Cytometer (Becton Dickinson) or CyAn ADP LX (Beckman
Coulter) and analyzed with FlowJo software (Tree Star). Prior to
analysis, all samples were gated using forward and side scatter to
exclude cellular debris.
Immunoblot
Total cellular proteins were harvested as previously described
[26]. Following a wash in 1x PBS, the cell pellets (approximately
3610
7 cells) were washed with cytoplasmic lysis buffer (10 mM
HEPES pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM dithio-
threitol [DTT], 0.2 mM phenylmethylsulfonyl fluoride [PMSF],
and 1x protease inhibitor cocktail [Roche] with protease inhibitors).
The pellets were resuspended in cytoplasmic lysis buffer, placed on
ice for 10 minutes, vortexed for 30 seconds, and pelleted. This swell-
vortex-pellet step was repeated prior to the resuspension of the
nuclear pellet in the nuclear lysis buffer (10 mM HEPES pH 7.9,
25% glycerol, 42 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA,
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Nuclei were resuspended in roughly equal volume of nuclear lysis
buffer. Following a 15-minute incubation on ice, DNA was pelleted
and the nuclear extracts were recovered. Approximately 1–5 mg of
protein as determined by modified Bradford Assay (Bio Rad) was
loaded into each lane of a 10% Bis-Tris gel (Invitrogen). Rabbit
anti-mTOR (Sigma; 1:1000), rabbit anti-S6K (Santa Cruz
Biotechnologies, Inc; 1:1000), rabbit anti-phospho-S6K (Sigma),
mouse anti-a-tubulin (Sigma; 1:2000); goat anti-RCC1 (Santa Cruz
Biotechnologies, Inc; 1:2000), mouse anti-HIF1-a (BD Biosciences;
1:400), mouse anti-vIRF3 (a kind gift from Y. Chang; 1:1000), and
rabbit anti-RTA (a kind gift from D. Lukac; 1:2000) were used to
probe the nitrocellulose membrane (Bio Rad). All antibodies were
diluted in 5% milk in TBS-Tween (0.5%) and secondary HRP-
conjugated antibodies were used at 1:10,000. Non-enzymatic
immunoblots were stained with anti-mouse or anti-rabbit IgG
antibodies conjugated to Infrared Dye 680 or 800 and images
scanned and analyzed using Odyssey Infrared Imaging System and
3.0 Software (Licor Biosciences).
Real-time PCR
TotalRNAwasisolatedfromBCBL-1cellsusingQiagenRNeasy
RNA Isolation Kit (Qiagen Inc., Valencia, CA). Briefly, cells were
pelleted, supernatant removed and pellet resuspended in RLT lysis
buffer. Lysates were homogenized by loading onto Qiashredder
columns (Qiagen, Inc.), spinning at 13,000K x 2 min. Homoge-
nized lysates were stored at 280uC until further purification. Total
RNA was treated with on-column DNase (Qiagen, Inc) and again
after elution from RNA columns using Ambion DNA-free kit (Life
Technologies, Carlsbad, CA). cDNA was generated from 1 ug of
RNA using Omniscript reverse transcriptase (Qiagen) and oligo-dT
primers to generate template for GAPDH quantification and an
ORF50-specific reverse primer (59 GGAGAGGGACTACTG-
TTGG 39) to generate template for ORF50 mRNA quantification.
Real-time PCR using forward and reverse DNA primers (IDT) and
labeled FAM-BHQ1 probes (Biosearch Technologies) was done in
triplicate on diluted cDNA using Taqman Universal PCR Mix
(Applied Biosystems) and analyzed by UVA DNA Sciences using an
ABI PrismH 7900 HT Detection System.
ORF50 primer/probe set:
Fwd – TTGTCGCAGAGAACACCGG
Rev – GCAAGGGTGACATGACGTCA
Probe – CAAGCTTCCCGTTCTCAGCC
GAPDH primer/probe set:
Fwd – GATTCCACCCATGGCAAATT
Rev – GAAGATGGTGATGGGATTTCCA
Probe – CAAGCTTCCCGTTCTCAGCC
All ORF50 transcripts were normalized to GAPDH for analysis.
Statistical analyses
Population means were assessed for statistical significance using
an unpaired t test to calculate two-tailed p values. All analyses
were done using the built-in statistical algorithms in GraphPad
Prism 4.0 software. The results from these analyses are stated in
the legends or indicated within the figure. P values less than 0.05
were considered statistically significant.
Results
Rapamycin blocks S6K phosphorylation in BCBL-1 cells
without substantial changes in cell proliferation or cell
cycle
mTOR can play an important role in regulating the cell cycle
and rapamycin, an inhibitor of mTOR signaling, appears to
control the growth of several KSHV-associated tumors [14].
However, not all types of KSHV
+ tumors are comparably
susceptible to rapamycin-mediated growth inhibition and, impor-
tantly, the viral lytic (productive) cascade is a critical component of
pathogenesis for KSHV
+ tumors [3,4]. Thus, we sought to
determine whether in KSHV
+ cells, treatment with rapamycin
might also directly affect the viral life cycle. To separate the effects
of cell cycle perturbation from changes in viral gene expression, we
conducted experiments using a cell line that is relatively resistant
to profound growth arrest with rapamycin treatment[14]. We
verified the rapamycin resistance of this KSHV
+EBV
- primary
effusion lymphoma cell line, BCBL-1 [23], to growth arrest by
treating with the drug and assessing cell cycle profiles. Following
48 hours of treatment of BCBL-1 with a range of rapamycin doses,
we harvested and then stained the cells with the DNA dye
propidium iodide to measure cellular DNA content using flow
cytometry. We found that increasing amounts of rapamycin
minimally affected the cell cycle profile, though at the highest
dose, 120 nM, some inhibition was evident (Figure 1A and B).
These results contrasted, not surprisingly, with the effects of the
protein synthesis inhibitor, cycloheximide, which caused dose-
dependent decreases in the proportion of the population in S
phase and concurrent accumulation in G1 and G2/M (not shown)
[27,28]. To verify the inhibition of mTOR function in these cells
despite the lack of cell cycle arrest, we assessed inhibition of
mTOR function in drug-treated cells by immunoblotting for
phosphorylation of its downstream target, S6 kinase. As with other
cell types[29–31], treatment of BCBL-1 cells with rapamycin for
two days resulted in a specific loss of phosphorylated p70 S6 kinase
(S6K) at position Thr
389 (Fig. 1C).
Spontaneous and induced RTA expression is decreased
in rapamycin-treated BCBL-1 cells
Clinical observations suggest that active viral production of
KSHV is associated with pathogenesis and that rapamycin inhibits
the formation of Kaposi’s sarcoma [3,13,32–36]. Therefore, we
next investigated the potential role of mTOR (and its blockade by
rapamycin) in lytic replication of the virus. Using RT-PCR, Sin
and colleagues found that rapamycin has no discernable effect on
baseline levels of viral transcripts among latently infected PEL
lines [14]. As a result, we hypothesized that mTOR inhibition may
modulate lytic KSHV replication through post-transcriptional
effects; therefore, we examined viral protein levels in the presence
and absence of mTOR inhibition. As RTA is both necessary and
sufficient for the initiation of the lytic cascade, we focused our
attention on determining the effects of rapamycin on levels of this
critical latent-to-lytic switch protein [5,6]. After treating BCBL-1
cells with rapamycin for two days, we employed immunoblots to
assess relative levels of RTA within nuclear protein extracts, using
the nuclear protein RCC1 (regulator of chromosome condensation
1) as a loading control (Figure 2A). We found a low level of
spontaneous RTA expression in the vehicle treated BCBL-1
population; however, with rapamycin treatment, RTA became
undetectable. We verified this finding using intracellular antibody
staining and flow cytometric analysis, observing a greater than
50% reduction in the number of BCBL-1 cells spontaneously
expressing RTA at detectable levels (Fig. 2B, top panels). We next
tested the ability of rapamycin treatment to suppress RTA levels in
the presence of a potent lytic cycle inducing agent, VPA. As we
expected, addition of VPA to BCBL-1, in the absence of mTOR
inhibition, led to a robust increase in RTA levels by 48 hrs. In
stark contrast, pre-treatment with rapamycin almost completely
blocked this induction (Fig. 2A). Again, we confirmed this drop in
Rapamycin Inhibits Lytic KSHV
PLoS ONE | www.plosone.org 3 January 2011 | Volume 6 | Issue 1 | e14535RTA expression by flow cytometric analysis of live cells stained for
RTA expression (Fig. 2B, bottom).
Rapamycin inhibition of RTA expression is dose-
dependent and independent of the induction reagent
To assess more precisely the degree of RTA inhibition by
rapamycin, we treated BCBL-1 cells with increasing concentra-
tions of the drug and quantified RTA levels using non-enzymatic
infrared detection and analysis of immunoblot bands (Fig. 2C).
Rapamycin, at doses as low as 1.2 nM, reduced average RTA
levels by more than 90%. Since 12 nM rapamycin more closely
approximates the target serum trough levels maintained in patients
during treatment [15,18,37], we used this dose for most of our
experiments. Again, we verified the immunoblot results at the
single cell level using flow cytometric analysis and found the
proportion of BCBL-1 cells expressing RTA decreased with
increasing concentrations of rapamycin (Fig. 2D). Although only
limited information exists for the mechanisms involved in chemical
reactivation of KSHV, lytic cycle induction by VPA depends on its
functions as an HDAC inhibitor [8]. To determine whether the
suppression of lytic gene expression by rapamycin was limited to
this specific type of reactivation stimulus, we tested BCBL-1
treated with either TPA, which activates the ERK/MAPK
pathway, or CoCl2, which acts as a hypoxia mimetic (activating
RTA via HIF1a) to induce RTA expression [10,11]. Briefly, we
treated BCBL-1 with rapamycin and then, following incubation
with either TPA or CoCl2, used immunoblots (Fig 2E) to measure
levels of RTA expression. Regardless of the lytic inducing drug or
its dose, we detected a dramatic loss of RTA expression in
rapamycin treated cells. We verified these immunoblot results
using flow cytometry to detect intracellular RTA staining across
multiple experiments (Fig. 2F). Of note, we also consistently
observed that in the absence of any inducing agent, rapamycin
resulted in the loss of baseline (spontaneous) RTA expression
(Fig. 2A,B and E). Together, these results suggested that mTOR
Figure 1. Rapamycin blocks S6K phosphorylation in BCBL-1 cells, but does not block cell cycle progression. (A) DNA content analysis of
BCBL-1 cells treated with rapamycin (0.12 nM, 12 nM, 120 nM) or DMSO vehicle control was determined by PI staining (representative experiment of
n$3). (B) Graph of percentage of cells in either the G1, S, G2 subset as determined using the Modfit LT analysis software. (C) BCBL-1 cells treated with
rapamycin at indicated doses. At 48 hours post-treatment, whole cell extracts were immunoblotted for mTOR, S6K phosphorylated at Thr
389, and S6K.
doi:10.1371/journal.pone.0014535.g001
Rapamycin Inhibits Lytic KSHV
PLoS ONE | www.plosone.org 4 January 2011 | Volume 6 | Issue 1 | e14535Figure 2. Rapamycin inhibits spontaneous and induced RTA expression in a dose-dependent manner regardless of induction
pathway. BCBL-1 were treated with 120 nM rapamycin or vehicle for 2 h, and then without (uninduced) or with 0.6 mM VPA (induced). (A) 48 h
post-treatment, nuclear extracts were analyzed by immunoblot for RTA expression using the nuclear protein, RCC1, as a loading control.
Representative experiment, n=3. (B) 48 h post-rapamycin, uninduced BCBL-1 cells (top panels) or VPA-induced (bottom panels) were harvested,
treated with a dead cell stain, then fixed, stained for intracellular RTA, and analyzed by flow cytometry. Representative plots (n=7) show RTA
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clinically significant, spontaneous mechanisms of lytic reactivation.
We next investigated the potential effect of rapamycin (and loss
of mTOR activity) on the expression of other proteins to assess its
relative specificity for RTA expression. We asked whether
inhibition of RTA expression simply reflected a global shutdown
of all protein synthesis within the treated cells. To address the
possibility that some proteins might have long half-lives,
potentially confounding our analyses of rapamycin’s effects, we
took advantage of previously established data demonstrating that
CoCl2 results in the de novo transcription and subsequent protein
expression of both RTA and HIF1a [10,11]. In contrast to the
profound suppression of CoCl2-induced RTA expression with the
lowest doses of rapamycin (Figure 3A), CoCl2-induction of HIF1a
was only minimally affected even with the highest doses (120 nM)
of rapamycin (Figure 3A, left panel; we also obtained similar
results at 48 hours). We next assessed the two latent proteins, viral
interferon regulatory factor-3 (vIRF-3) and the latency-associated
nuclear antigen (LANA). Immunoblots revealed that rapamycin
treatment (with or without induction) had no appreciable effect on
these two proteins (Figure 3A, middle and right). We predicted
that rapamycin-suppression of RTA would result in commensu-
rate changes in downstream lytic genes. Flow cytometry, in fact,
revealed that rapamycin treatment led to reductions ranging from
43 to 72 percent in the levels of both the delayed-early protein
ORF59 (processivity factor) and the late glycoprotein K8.1. This
effect was evident in both uninduced and induced cultures (see
Figure 3B dot blot for ORF59 and scatter graph representations
for ORFs 59 and 8.1). In contrast, rapamycin had little effect on
the percentage of cells positive for LANA (Figure 3B, rightmost
panel). (Although the differences in LANA expression with and
without rapamycin reached statistical significance, the variation
was under 8%.) Thus, while mTOR can regulate multiple cellular
response pathways, rapamycin appeared to have a disproportion-
ate impact on RTA and its downstream lytic genes compared to
cellular or latent viral proteins.
Rapamycin mediates its inhibition of RTA expression via
both transcriptional and post-transcriptional
mechanisms
Although the metabolic effects of mTOR inhibition are protean,
much of the research in this area has focused on the resulting
down-regulation of translation. Therefore, we asked if the relative
decrease in RTA protein levels in rapamycin treated BCBL-1 cells
occurred in the absence of decreases in ORF50 (RTA) mRNA
levels. We measured both ORF50 mRNA and RTA protein levels
in cultures pre-treated with rapamycin for 2 hours and then
incubated with VPA to induce lytic reactivation of KSHV
(Fig. 4A). We collected samples at 0, 6, 24, and 48 hours post-
VPA addition and then determined RTA protein levels by
quantitative immunoblotting (Fig 4A, top) and, in parallel samples,
ORF50 mRNA levels by quantitative RT-PCR (Fig 4A, bottom).
While the magnitude of RTA expression was variable between
experiments compared to vehicle-treated samples, rapamycin
consistently suppressed RTA levels at the 24-hour time point
while the ORF50 mRNA levels remained essentially unchanged.
This suggested, as we had expected for mTOR inhibition, that a
post-transcriptional block at least partially mediated the decrease
in RTA protein. By 48 hours, the rapamycin suppression of RTA
levels was even more pronounced but we also observed an
approximately 2-fold decrease in ORF50 mRNA levels within the
drug-treated populations.
Although for VPA-induced cells the drop in protein appeared to
precede change in mRNA, we noted that for TPA- and CoCl2-
induced cells, there was a modest reduction (mean 1.6 and 2.4
fold, respectively) in mRNA at 24 h (Fig. 4B). Therefore, we were
unable to exclude transcriptional regulation of RTA expression
during the activation of these pathways in the presence of
rapamycin. Regardless of induction method, we noted an
approximate 2-fold decrease in ORF50 mRNA and a 2- to 10-
fold drop in RTA protein levels by 48 hours (Fig. 4).
Since previous work has shown that rapamycin can directly
arrest growth of a number of cancer lines, including a subset of
PEL lines, we ascertained that the observed decreases in mRNA
and protein did not reflect overall cell viability. Cell viability in
DMSO versus rapamycin treated cultures was similar for all
inducing conditions and time points (Fig. 4C). Together, the data
suggested that rapamycin significantly inhibited RTA expression
relative to other cellular and viral proteins and that a combination
of transcriptional and post-transcriptional effects rather than a loss
of cell viability or global suppression mediated this inhibition.
Commensurate reduction in release and transmission of
infectious virions
While RTA is necessary and sufficient for initiating viral lytic
replication, it is only the initial measure of the productive phase of
infection. Clinically, the most important read-out is the production
of virions. To assess this parameter, we treated BCBL-1 cells with
rapamycin, induced with VPA, TPA, or CoCl2 and then measured
viral titers five days later. As we have shown previously in KSHV-
infected cells, the number of punctate aggregates of virally-
encoded latency-associated nuclear antigen (LANA), or ‘‘LANA
dots’’, correspond to the number of KSHV episomes present in the
nucleus[38]. Thus, following de novo infection of KSHV-
susceptible cells, the resulting LANA dots reflect the titer in the
inoculum. Briefly, following each treatment we harvested media
pre-cleared of cellular debris, collected the virus by centrifugation,
and then incubated serial dilutions of the resuspended viral pellet
with HeLa cells in the presence of polybrene. We measured titers
of infectious virus by staining the KSHV-exposed HeLa cells for
LANA and analyzing cells using multispectral imaging flow
cytometry (MIFC) to determine the number of punctate LANA
dots per cell. As evident in Figure 5A, rapamycin treatment
decreased the amount of virus produced from BCBL-1 cells
treated with VPA, TPA, or CoCl2 by 9.3, 9.7, and 7.7 fold,
respectively.
expression in live-gated BCBL-1 cells treated with vehicle (left panels) or rapamycin (right panels). (C) Nuclear extracts were analyzed for RTA
expression using non-enzymatic infrared detection probes to quantify relative protein levels. Ran (ras-related nuclear protein) was used as loading
control. Graph (C, bottom panel) shows immunoblot RTA levels normalized to Ran as a percentage of RTA levels in the vehicle (DMSO) treated
control. Representative experiment (n=2). (D) Induced BCBL-1 cells treated for 48 h with rapamycin at indicated doses were fixed, stained for
intracellular RTA and analyzed by flow cytometry. Graph, right, shows percent of RTA
+ cells in population indicated by histogram gate. (E) BCBL1 48 h
post-treatment cells were harvested and nuclear extracts immunoblotted for RTA and normalized to Ran. Graph shows quantification of bands using
non-enzymatic infrared detection probes. Representative experiment (n=2). (E) BCBL-1 treated with indicated doses of rapamycin and left uninduced
(square, dashed line), or induced with either VPA (triangle, solid line), TPA (triangle, dashed line), or CoCl2 (open triangle, solid line) were cultured for
48 hrs in presence of rapamycin, then stained with intracellular RTA. Graph shows percentage of RTA
+ cells in live cell population. Mean 6 s.e.m.; n
for each condition shown in parentheses.
doi:10.1371/journal.pone.0014535.g002
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viral propagation in the clinical setting, we assessed whether
rapamycin similarly diminished virus release from uninduced
BCBL-1 cells. The rate of spontaneous lytic reactivation, a
correlate of virion release, is low in PEL cells in culture. We have
previously found that de novo infection of naı ¨ve cells by KSHV is
more efficient when the virus is cell-associated rather than cell-free
and, thus, a more sensitive means of detecting low levels of
infectious virion production in the laboratory setting [24].
Therefore, we assessed whether rapamycin was able to signifi-
cantly decrease cell-to-cell transfer of KSHV from BCBL-1 to co-
cultured HeLa cells. Mirroring our observations with the induced
populations, we found that rapamycin also markedly decreased the
levels of infectious virion production in spontaneously lytic BCBL-
1 cells compared to titers from vehicle treated controls (Fig. 5C).
Discussion
In this study we have shown that lytic reactivation of KSHV was
partially controlled via mTOR signaling. Using a KSHV
+ PEL
line resistant to rapamycin-mediated growth inhibition, we
demonstrated that in the absence of cell cycle arrest and death
rapamycin was able to repress expression of the KSHV lytic
master switch protein, RTA, and significantly impair virion
production. Rapamycin, upon binding with FK506-binding
protein 12 (FKBP12), inhibits several downstream functions of
Figure 3. Rapamycin treatment significantly decreases induction of lytic KSHV proteins. (A) BCBL-1 cells were pre-treated for 2 hours with
rapamycin (12 nM), then induced, in the presence of rapamycin with either CoCl2 or TPA. (A) BCBL-1 cells were pre-treated for 2 hours with
rapamycin 120 nM or DMSO vehicle control two hours prior to induction with CoCl2 (200 mM), TPA (20 ng/mL) or VPA (600 mM). Nuclear extracts
were analyzed by immunoblot for HIF1a expression 24 hours (left), or vIRF3 expression (middle) or LANA expression (right) 48 hours post-treatment.
(B) Uninduced or VPA-induced BCBL-1 cells were harvested 48 h post-rapamycin treatment (12 nM), then fixed and stained with antibodies against
ORF59, K8.1 and LANA. Leftmost set of dot plots show ORF59 staining on representative samples from uninduced (left panels) and induced (right
panels) BCBL-1 cells treated with either vehicle (top panels) or rapamycin (bottom panels). Similar data was collected for both K8.1 and LANA
expression. Graphs depict results from multiple replicates of these experiments and indicate the percent of live-gated cells positive for indicated
protein stain; horizontal lines depict the mean of replicates (individual circles). Numbers above graph depict p values of comparisons.
doi:10.1371/journal.pone.0014535.g003
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translation and inhibit cell cycle causing G1 arrest [39]. More
specifically, rapamycin can cause growth arrest in B cell
lymphomas including subsets of EBV
+ and of KSHV
+ tumors
[14,40–42]. However, in contrast to many EBV infected [42] and
uninfected B cells [40,41], we found that in BCBL-1 cells
rapamycin inhibition of mTOR function (reflected by the loss of
S6K phosphorylation at Thr
389) could be dissociated from
significant arrest of cell cycle (Fig. 1) and loss of viability (Fig. 5).
This finding is also in agreement with the work by Sin et al. that
demonstrated that the responsiveness of KSHV-infected PEL cell
lines to rapamycin growth arrest is highly variable [14]. By taking
advantage of this cell line in which cell cycle arrest was dissociated
from other rapamycin-mediated effects, we demonstrated that
rapamycin treatment of cells inhibited the viral lytic cycle.
A wide range of DNA viruses activate the mTOR signaling
pathway [43]. Herpesviruses, including KSHV, are well repre-
sented among this group. A primary pathway activating mTOR
signaling involves PI3K-dependent growth factor signaling and
both EBV and KSHV up-regulate the PI3K/Akt signaling
pathway leading to mTOR activation [21,44–47]. Activation of
mTOR is also evident in KSHV-associated tumors [14,15].
However, mTOR can receive information from a wide variety
of upstream signaling pathways, including cytokine, growth
factor, nutrient and stress sensors[48]. Work with EBV[42,49]
and the Sin et al. study [14] suggest that rapamycin might
suppress KSHV-associated disease through non-virally associated
cytokine dysregulation and control of tumor growth. The
mechanism underlying the cellular resistance to rapamycin-
mediated growth arrest, at least in a subset of PEL cell lines,
remains unknown, though it might reflect the single or combined
effects of several viral proteins expressed in infected cells that have
the potential to dysregulate the cell cycle and disrupt apoptotic
pathways [45,50–56].
We have shown here that mTOR signaling is necessary for full
expression of KSHV lytic proteins. Of interest, it has been
previously demonstrated that vGPCR, also a lytic gene down-
stream of RTA, can upregulate mTOR activation, contributing to
tumorigenesis via its promotion of growth and angiogenesis factors
([21,57] and reviewed in [58]). Bottero et al. have more recently
Figure 4. RTA regulation by rapamycin is mediated at both the mRNA and protein level. Messenger ORF50 RNA and RTA protein levels
were assessed in BCBL-1 pre-treated with rapamycin for 2 hours, and then induced to lytic reactivation using VPA, TPA, or CoCl2. Samples were
collected at 0, 6, 24, and 48 hours post-treatment. (A) Top panel, nuclear extracts were used to determine RTA protein levels at each time point using
non-enzymatic, immunoblot quantification and normalization to Ran. Graphs show mean 6 s.e.m. of triplicate experiments for DMSO (solid line) and
rapamycin-treated (dashed line) samples. Individual experiments were normalized to the maximal protein expression levels in DMSO sample at 48 h
post-induction. Bottom panel, total mRNA was also collected for quantitative RT-PCR analysis of ORF50 mRNA from parallel whole lysate samples.
Graph shows pooled data from 3 experiments with DMSO (solid line) and rapamycin-treated (dashed line) cultures shown. Means 6 s.e.m. (B) BCBL-1
cells treated with rapamycin (dashed lines) or DMSO (solid lines) were induced with either TPA (left panels) or CoCl2 (right panels). RTA protein levels
(top) and mRNA levels (bottom) are shown from representative experiments. (C) For each timepoint and induction, viability was determined for both
DMSO (black bar) and rapamycin-treated (gray bar) samples by staining an aliquot from each culture with a live/dead exclusion dye and assessing for
dye uptake (cell death) by flow cytometry. Graphs show % viable, mean 6 s.e.m. of triplicates.
doi:10.1371/journal.pone.0014535.g004
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Thus, the expression of vGPCR following the initiation of the lytic
cycle likely enhances RTA levels by activating mTOR and
enhancing SP1/SP3 mediated transcription of ORF50, providing
a positive lytic feedback loop that may promote virion production
[59]. It is conceivable that growth inhibition in rapamycin
sensitive KSHV-infected tumors combined with the lytic cycle
suppression that we have described in the rapamycin-resistant
BCBL-1 line could act synergistically to result in an overall loss of
productive infection and subsequent pathogenesis. The flip side of
this synergism is that treatment with an mTOR inhibitor impacts
KSHV tumors both by inhibiting tumorigenic growth, and
angiogenesis, as well as by reducing virus production.
Our report is the first to show rapamycin sensitivity of viral
replication for a herpesvirus, though a recent study has described the
opposite finding: a rapamycin-insensitive mTOR-dependent replica-
tion pathway for HCMV [60]. These diverse results highlight the
broadrolethatmTORhasasadownstreameffectorofmanysignaling
pathways. We have examined the effects of rapamycin treatment on
virus production and have shown that expression of KSHV RTA was
rapamycin sensitive. Further, this repression of RTA expression, and
ultimately virion production, occurred in a dose dependent manner
irrespective of the induction pathway leading to the lytic cycle (Fig 2).
Remarkably,rapamycintreatmentalso decreased the baseline levelsof
RTA expressed from the small percentage of cells undergoing
spontaneous lytic reactivation (Figure 2A). These data suggested that
mTOR plays an essential physiologic role in viral reactivation rather
than being restricted to induction pathways initiated by the addition of
exogenous chemical agents.
The exact mechanism(s) through which mTOR inhibition
mediated its repressive effects on RTA expression was less clear.
Our results suggest that the rapamycin-dependent inhibition of
RTA might have occurred, in large part, at the level of translation,
consistent with the role of rapamycin as a translation inhibitor
[20]. We found that rapamycin dramatically decreased protein
levels of RTA without requiring either concomitant global
shutdown of cellular translation (Fig. 3A) or a decrease in
ORF50 mRNA (Fig. 4). These findings were most evident when
we tested the effects of rapamycin on cells induced with VPA.
However, with either TPA- or CoCl2- induced cells, we also noted
rapamycin-associated down-regulation of ORF50 mRNA. Previ-
ous work with HIV-1 and HTLV-1 has revealed that rapamycin-
mediated inhibition of viral transcription results in decreased
retroviral replication [61,62]. For HTLV-1 this transcriptional
regulation is linked to down-regulation of the transcription factor,
c-Myb [61], rather than being a direct property of the mRNA itself
as evident in the mTOR-mediated translational control of 59-
terminal oligo-pyrimidine-containing mRNA [63,64]. Given the
heterogeneity of the effects on ORF50 mRNA levels downstream
of the different induction signals, it is likely that rapamycin
treatment negatively affected one or more transcription factors.
Thus, it is not surprising that rapamycin could have varied
transcriptional effects in addition to post-transcriptional effects
under the different induction conditions we examined.
Of note, recent work from Arias et al. demonstrated little effect
of rapamycin on RTA expression in the TREx-RTA BCBL-1 line
that are stably transduced with a doxycycline-inducible RTA
construct. In this cell line, inducible RTA is robustly expressed
Figure 5. Virion production is significantly decreased by rapamycin treatment. BCBL-1 +/2 rapamycin 12 nM were induced with CoCl2,
TPA, or VPA. Five days post-induction, virus was concentrated from supernatants. HeLa cells were then infected with concentrated virus in the
presence of polybrene. Viral titers were determined by staining HeLa cells for punctate intranuclear LANA dots and analyzing via multispectral
imaging flow cytometry. (A) Images show representative nuclear staining with DRAQ5 (Nuc.), LANA antibody stain, and the overlay (Comb.). Upper
panel shows three representative HeLa cells infected with inoculum from untreated VPA-induced BCBL-1. Lower panel shows representative HeLas
infected with inoculum from rapamycin-treated VPA-induced cells. (B) Graph of viral titers untreated (black bars) or treated with rapamycin (gray bars)
for each indicated inducting agent. Representative experiment, n=2. (C) Inhibition of cell-to-cell virus transmission from spontaneously lytic BCBL-1
was assessed by culture of BCBL-1 in the presence of 12 nM rapamycin for 2 days. Cells were then harvested, placed in fresh media without
rapamycin and co-cultured with HeLa cells for 24 h. BCBL-1 cells were removed, HeLa cells washed x 2 to remove non-adherent BCBL-1 cells, and
cultured an additional 24 h before harvest. Adherent HeLa cells were trypsinized, fixed and stained for intranuclear LANA dots. LANA
+ HeLa cells were
analyzed by MIFC. Graph shows percentage (mean 6 s.d.) of infected cells from triplicate cultures for HeLa cells co-cultured with either rapamycin-
treated (gray) or DMSO-treated (black) BCBL-1. ** p,0.01.
doi:10.1371/journal.pone.0014535.g005
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rapamycin-insensitive in several systems[66,67]. Low 4EBP1
phosphorylation reported in the TREx-RTA BCBL1 suggests
that mTOR activity is also low in the line used for these studies,
and may not reflect the mTOR activity of the parental line[68].
The group’s finding that RTA could be post-transcriptionally
down-regulated via blockade of Mnk activity is of particular
importance, however, as it suggests an additional path with which
to block lytic KSHV, particularly in patient tumors that are
resistant to rapamycin inhibition.
Together, our results have provided a virally based explanation
for the somewhat paradoxical clinical observations linking the
immunosuppressant, rapamycin, to the control of the opportunis-
tic malignancy, KS. Consistent with our findings, Barozzi et al.
reported that the switch to a rapamycin-containing immunosup-
pressant regimen in a post-renal transplant patient led to a
decrease in peripheral viral load that preceded any increase in T
cell responses or the subsequent regression of KS lesions[22].
While anecdotal, this observation supports our data showing that
rapamycin can suppress virus production. While further studies
are necessary to elucidate the molecular details governing
mTOR’s role in RTA expression, our results have provided the
first demonstration that rapamycin inhibited RTA expression and
viral production. These findings have provided a potential
molecular explanation for the anti-KS effects of rapamycin that
further justify its continued study and use in preventing and
treating KSHV-associated tumors in transplant patients.
Acknowledgments
We thank J. Lannigan and M. Solga (UVA flow cytometry core), D. Lukac
(NJ Medical School) and K. Ueda (Osaka University) for providing
antibodies to RTA, P. Moore and Y. Chang (University of Pittsburgh) for
the vIRF-3 antibodies.
Author Contributions
Conceived and designed the experiments: LAN LAA DHK. Performed the
experiments: LAN LAA. Analyzed the data: LAN LAA DHK. Wrote the
paper: LAN LAA DHK.
References
1. Moore PS, Chang Y (2001) Molecular virology of Kaposi’s sarcoma-associated
herpesvirus. Philosophical Transactions of the Royal Society of London Series B-
Biological Sciences 356: 499–516.
2. Moore PS, Gao SJ, Dominguez G, Cesarman E, Lungu O, et al. (1996) Primary
characterization of a herpesvirus agent associated with Kaposi’s sarcoma.
Journal of Virology 70: 549–558.
3. Grundhoff A, Ganem D (2004) Inefficient establishment of KSHV latency
suggests an additional role for continued lytic replication in Kaposi sarcoma
pathogenesis. J Clin Invest 113: 124–136.
4. Casper C, Nichols WG, Huang ML, Corey L, Wald A (2004) Remission of
HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir
treatment. Blood 103: 1632–1634.
5. Lukac DM, Kirshner JR, Ganem D (1999) Transcriptional activation by the
product of open reading frame 50 of Kaposi’s sarcoma-associated herpesvirus is
required for lytic viral reactivation in B cells. J Virol 73: 9348–9361.
6. Xu YY, AuCoin DP, Huete AR, Cei SA, Hanson LJ, et al. (2005) A Kaposi’s
sarcoma-associated herpesvirus/human herpesvirus 8 ORF50 deletion mutant is
defective for reactivation of latent virus and DNA replication. Journal of
Virology 79: 3479–3487.
7. Sun R, Lin SF, Gradoville L, Yuan Y, Zhu FX, et al. (1998) A viral gene that
activates lytic cycle expression of Kaposi’s sarcoma-associated herpesvirus.
Proceedings of the National Academy of Sciences of the United States of
America 95: 10866–10871.
8. Shaw RN, Arbiser JL, Offermann MK (2000) Valproic acid induces human
herpesvirus 8 lytic gene expression in BCBL-1 cells. Aids 14: 899–902.
9. Yu YM, Black JB, Goldsmith CS, Browning PJ, Bhalla K, et al. (1999) Induction
of human herpesvirus-8 DNA replication and transcription by butyrate and TPA
in BCBL-1 cells. Journal of General Virology 80: 83–90.
10. Cai Q, Lan K, Verma SC, Si H, Lin D, et al. (2006) Kaposi’s sarcoma-
associated herpesvirus latent protein LANA interacts with HIF-1 alpha to
upregulate RTA expression during hypoxia: Latency control under low oxygen
conditions. J Virol 80: 7965–7975.
11. Davis DA, Rinderknecht AS, Zoeteweij JP, Aoki Y, Read-Connole EL, et al.
(2001) Hypoxia induces lytic replication of Kaposi sarcoma-associated
herpesvirus. Blood 97: 3244–3250.
12. Yilmaz R, Akoglu H, Kirkpantur A, Kilickap S, Arici M, et al. (2007) A Novel
Immunosuppressive Agent, Sirolimus, in the Treatment of Kaposi’s Sarcoma in
a Renal Transplant Recipient. Ren Fail 29: 103–105.
13. Kolhe N, Mamode N, Van der Walt J, Pattison J (2006) Regression of post-
transplant Kaposi’s sarcoma using sirolimus. Int J Clin Pract 60: 1509–1512.
14. Sin SH, Roy D, Wang L, Staudt MR, Fakhari FD, et al. (2007) Rapamycin is
efficacious against primary effusion lymphoma (PEL) cell lines in vivo by
inhibiting autocrine signaling. Blood 109: 2165–2173.
15. Stallone G, Schena A, Infante B, Di Paolo S, Loverre A, et al. (2005) Sirolimus for
Kaposi’s sarcoma in renal-transplant recipients. N Engl J Med 352: 1317–1323.
16. Merimsky O, Jiveliouk I, Sagi-Eisenberg R (2008) Targeting mTOR in HIV-
Negative Classic Kaposi’s Sarcoma. Sarcoma 2008: 825093.
17. Charfi S, Krichen-Makni S, Yaich S, Makni H, Khabir A, et al. (2007)
Successful treatment of post-renal transplant gastric and pulmonary Kaposi’s
sarcoma with conversion to rapamycin treatment. Saudi J Kidney Dis Transpl
18: 617–620.
18. Garcia VD, Bonamigo Filho JL, Neumann J, Fogliatto L, Geiger AM, et al.
(2003) Rituximab in association with rapamycin for post-transplant lymphopro-
liferative disease treatment. Transpl Int 16: 202–206.
19. Gutierrez-Dalmau A, Sanchez-Fructuoso A, Sanz-Guajardo A, Mazuecos A,
Franco A, et al. (2005) Efficacy of conversion to sirolimus in posttransplantation
Kaposi’s sarcoma. Transplant Proc 37: 3836–3838.
20. Averous J, Proud CG (2006) When translation meets transformation: the mTOR
story. Oncogene 25: 6423–6435.
21. Sodhi A, Chaisuparat R, Hu J, Ramsdell AK, Manning BD, et al. (2006) The
TSC2/mTOR pathway drives endothelial cell transformation induced by the
Kaposi’s sarcoma-associated herpesvirus G protein-coupled receptor. Cancer
Cell 10: 133–143.
22. Barozzi P, Riva G, Vallerini D, Bosco R, Quadrelli C, et al. (2009) Indirect
antitumor effects of mammalian target of rapamycin inhibitors against Kaposi
sarcoma in transplant patients. Transplantation 88: 597–598.
23. Renne R, Zhong W, Herndier B, McGrath M, Abbey N, et al. (1996) Lytic
growth of Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) in
culture. Nat Med 2: 342–346.
24. Tomescu C, Law WK, Kedes DH (2003) Surface downregulation of major
histocompatibility complex class I, PE-CAM, and ICAM-1 following de novo
infection of endothelial cells with Kaposi’s sarcoma-associated herpesvirus.
J Virol 77: 9669–9684.
25. Lacombe F, Belloc F, Bernard P, Boisseau MR (1988) Evaluation of four
methods of DNA distribution data analysis based on bromodeoxyuridine/DNA
bivariate data. Cytometry 9: 245–253.
26. Kremer BE, Haystead T, Macara IG (2005) Mammalian septins regulate
microtubule stability through interaction with the microtubule-binding protein
MAP4. Mol Biol Cell 16: 4648–4659.
27. Sun R, Lin SF, Staskus K, Gradoville L, Grogan E, et al. (1999) Kinetics of
Kaposi’s sarcoma-associated herpesvirus gene expression. J Virol 73:
2232–2242.
28. Zhu FX, Cusano T, Yuan Y (1999) Identification of the immediate-early
transcripts of Kaposi’s sarcoma-associated herpesvirus. J Virol 73: 5556–5567.
29. Chung J, Kuo CJ, Crabtree GR, Blenis J (1992) Rapamycin-FKBP specifically
blocks growth-dependent activation of and signaling by the 70 kd S6 protein
kinases. Cell 69: 1227–1236.
30. Kuo CJ, Chung J, Fiorentino DF, Flanagan WM, Blenis J, et al. (1992)
Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase. Nature
358: 70–73.
31. Price DJ, Grove JR, Calvo V, Avruch J, Bierer BE (1992) Rapamycin-induced
inhibition of the 70-kilodalton S6 protein kinase. Science 257: 973–977.
32. Grandadam M, Dupin N, Calvez V, Gorin I, Blum L, et al. (1997)
Exacerbations of clinical symptoms in human immunodeficiency virus type 1-
infected patients with multicentric Castleman’s disease are associated with a high
increase in Kaposi’s sarcoma herpesvirus DNA load in peripheral blood
mononuclear cells. J Infect Dis 175: 1198–1201.
33. Oksenhendler E, Carcelain G, Aoki Y, Boulanger E, Maillard A, et al. (2000)
High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-
10, and C reactive protein correlate with exacerbation of multicentric castleman
disease in HIV-infected patients. Blood 96: 2069–2073.
34. Whitby D, Howard MR, Tenantflowers M, Brink NS, Copas a, et al. (1995)
Detection of Kaposi-Sarcoma Associated Herpesvirus in Peripheral-Blood of
Hiv-Infected Individuals and Progression to Kaposis-Sarcoma. Lancet 346:
799–802.
35. Gonzalez-Lopez MA, Rodrigo E, Gonzalez-Vela MC, Fernandez-Llaca H,
Arias-Rodriguez MA, et al. (2006) Posttransplant Kaposi’s sarcoma restricted to
Rapamycin Inhibits Lytic KSHV
PLoS ONE | www.plosone.org 10 January 2011 | Volume 6 | Issue 1 | e14535the site of a previous deep venous thrombosis: abrupt onset after withdrawal of
sirolimus. Dermatology 213: 30–33.
36. Wasywich CA, Croxson MC, van Doornum GJ, Coverdale HA, Ruygrok PN
(2006) Sirolimus for Kaposi’s sarcoma. J Heart Lung Transplant 25: 726–729.
37. Yatscoff RW, Wang P, Chan K, Hicks D, Zimmerman J (1995) Rapamycin:
distribution, pharmacokinetics, and therapeutic range investigations. Ther Drug
Monit 17: 666–671.
38. Adang LA, Parsons CH, Kedes DH (2006) Asynchronous progression through
the lytic cascade and variations in intracellular viral loads revealed by high-
throughput single-cell analysis of Kaposi’s sarcoma-associated herpesvirus
infection. J Virol 80: 10073–10082.
39. Sarbassov DD, Ali SM, Sabatini DM (2005) Growing roles for the mTOR
pathway. Curr Opin Cell Biol 17: 596–603.
40. Decker T, Hipp S, Ringshausen I, Bogner C, Oelsner M, et al. (2003)
Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced
expression of cyclin D3, cyclin E, cyclin A, and survivin. Blood 101: 278–285.
41. Wanner K, Hipp S, Oelsner M, Ringshausen I, Bogner C, et al. (2006)
Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse
large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab.
Br J Haematol 134: 475–484.
42. Vaysberg M, Balatoni CE, Nepomuceno RR, Krams SM, Martinez OM (2007)
Rapamycin inhibits proliferation of Epstein-Barr virus-positive B-cell lympho-
mas through modulation of cell-cycle protein expression. Transplantation 83:
1114–1121.
43. Buchkovich NJ, Yu Y, Zampieri CA, Alwine JC (2008) The TORrid affairs of
viruses: effects of mammalian DNA viruses on the PI3K-Akt-mTOR signalling
pathway. Nat Rev Microbiol 6: 266–275.
44. Sodhi A, Montaner S, Patel V, Gomez-Roman JJ, Li Y, et al. (2004) Akt plays a
central role in sarcomagenesis induced by Kaposi’s sarcoma herpesvirus-
encoded G protein-coupled receptor. Proc Natl Acad Sci U S A 101:
4821–4826.
45. Wang L, Dittmer DP, Tomlinson CC, Fakhari FD, Damania B (2006)
Immortalization of primary endothelial cells by the K1 protein of Kaposi’s
sarcoma-associated herpesvirus. Cancer Res 66: 3658–3666.
46. Lambert SL, Martinez OM (2007) Latent membrane protein 1 of EBV activates
phosphatidylinositol 3-kinase to induce production of IL-10. J Immunol 179:
8225–8234.
47. Moody CA, Scott RS, Amirghahari N, Nathan CO, Young LS, et al. (2005)
Modulation of the cell growth regulator mTOR by Epstein-Barr virus-encoded
LMP2A. J Virol 79: 5499–5506.
48. Wullschleger S, Loewith R, Hall MN (2006) TOR signaling in growth and
metabolism. Cell 124: 471–484.
49. Nepomuceno RR, Balatoni CE, Natkunam Y, Snow AL, Krams SM, et al.
(2003) Rapamycin inhibits the interleukin 10 signal transduction pathway and
the growth of Epstein Barr virus B-cell lymphomas. Cancer Res 63: 4472–4480.
50. Montaner S, Sodhi A, Ramsdell AK, Martin D, Hu J, et al. (2006) The Kaposi’s
sarcoma-associated herpesvirus G protein-coupled receptor as a therapeutic
target for the treatment of Kaposi’s sarcoma. Cancer Res 66: 168–174.
51. Watanabe T, Sugaya M, Atkins AM, Aquilino EA, Yang A, et al. (2003)
Kaposi’s sarcoma-associated herpesvirus latency-associated nuclear antigen
prolongs the life span of primary human umbilical vein endothelial cells.
J Virol 77: 6188–6196.
52. Fujimuro M, Wu FY, ApRhys C, Kajumbula H, Young DB, et al. (2003) A
novel viral mechanism for dysregulation of beta-catenin in Kaposi’s sarcoma-
associated herpesvirus latency. Nat Med 9: 300–306.
53. Bubman D, Guasparri I, Cesarman E (2007) Deregulation of c-Myc in primary
effusion lymphoma by Kaposi’s sarcoma herpesvirus latency-associated nuclear
antigen. Oncogene.
54. Friborg J, Jr., Kong W, Hottiger MO, Nabel GJ (1999) p53 inhibition by the
LANA protein of KSHV protects against cell death. Nature 402: 889–894.
55. Davis MA, Sturzl MA, Blasig C, Schreier A, Guo HG, et al. (1997) Expression of
human herpesvirus 8-encoded cyclin D in Kaposi’s sarcoma spindle cells. J Natl
Cancer Inst 89: 1868–1874.
56. Grundhoff A, Ganem D (2001) Mechanisms governing expression of the v-FLIP
gene of Kaposi’s sarcoma-associated herpesvirus. J Virol 75: 1857–1863.
57. Sodhi A, Montaner S, Patel V, Zohar M, Bais C, et al. (2000) The Kaposi’s
sarcoma-associated herpes virus G protein-coupled receptor up-regulates
vascular endothelial growth factor expression and secretion through mitogen-
activated protein kinase and p38 pathways acting on hypoxia-inducible factor
1alpha. Cancer Res 60: 4873–4880.
58. Jham BC, Montaner S (2010) The Kaposi’s sarcoma-associated herpesvirus G
protein-coupled receptor: Lessons on dysregulated angiogenesis from a viral
oncogene. J Cell Biochem 110: 1–9.
59. Bottero V, Sharma-Walia N, Kerur N, Paul AG, Sadagopan S, et al. (2009)
Kaposi sarcoma-associated herpes virus (KSHV) G protein-coupled receptor
(vGPCR) activates the ORF50 lytic switch promoter: a potential positive
feedback loop for sustained ORF50 gene expression. Virology 392: 34–51.
60. Moorman NJ, Shenk T (2010) Rapamycin-resistant mTORC1 kinase activity is
required for herpesvirus replication. J Virol 84: 5260–5269.
61. Rose NJ, Lever AM (2007) Rapamycin-induced inhibition of HTLV-I LTR
activity is rescued by c-Myb. Retrovirology 4: 24.
62. Roy J, Paquette JS, Fortin JF, Tremblay MJ (2002) The immunosuppressant
rapamycin represses human immunodeficiency virus type 1 replication.
Antimicrob Agents Chemother 46: 3447–3455.
63. Avni D, Biberman Y, Meyuhas O (1997) The 59 terminal oligopyrimidine tract
confers translational control on TOP mRNAs in a cell type- and sequence
context-dependent manner. Nucleic Acids Res 25: 995–1001.
64. Hornstein E, Git A, Braunstein I, Avni D, Meyuhas O (1999) The expression of
poly(A)-binding protein gene is translationally regulated in a growth-dependent
fashion through a 59-terminal oligopyrimidine tract motif. J Biol Chem 274:
1708–1714.
65. Nakamura H, Lu M, Gwack Y, Souvlis J, Zeichner SL, et al. (2003) Global
changes in Kaposi’s sarcoma-associated virus gene expression patterns following
expression of a tetracycline-inducible Rta transactivator. J Virol 77: 4205–4220.
66. Erbay E, Park IH, Nuzzi PD, Schoenherr CJ, Chen J (2003) IGF-II transcription
in skeletal myogenesis is controlled by mTOR and nutrients. J Cell Biol 163:
931–936.
67. Rose N, Lever A (2001) The rapamycin sensitivity of human T-cell leukaemia
virus type I-induced T-cell proliferation is mediated independently of the
polypyrimidine motifs in the 5’ long terminal repeat. J Gen Virol 82: 435–439.
68. Arias C, Walsh D, Harbell J, Wilson AC, Mohr I (2009) Activation of host
translational control pathways by a viral developmental switch. PLoS Pathog 5:
e1000334.
Rapamycin Inhibits Lytic KSHV
PLoS ONE | www.plosone.org 11 January 2011 | Volume 6 | Issue 1 | e14535